• Tuesday, September 22, 2020 @ 12:00 am

Newron has prioritized evenamide with blockbuster sales potential in schizophrenia and CTRS after sarizotan was discontinued in Rett syndrome when the pivotal “STARS” trial did not meet its endpoints in May. The two pivotal evenamide trials are on track to start in Q2 2021 with the success rate jumping to 50% (potentially pivotal) from currently 15% (POC). Sufficient funding has been secured. Newron is trading well below the value of Xadago approved in Parkinson’s disease with (low) royalties and milestone revenues. Substantial value will be unlocked with the approval and launch of evenamide in schizophrenia and CTRS, and Xadago in PD-LID.

Key catalysts include:

  • Results evenamide FDA explanatory “Study 008” (Q1 2020)
  • Start new label trial Xadago in PD-LID (H1 2020)
  • Start potentially pivotal program of evenamide in schizophrenia/CTRS (Q2 2020)

Read the full Newron Valuation Report